Maximal Response and Time to Progression After Administration of 375 mg/m2 Rituximab Once Weekly for Four Weeks
| Patient . | Lymphocyte Counts (×109/L) at Baseline . | Response . | Time to Progression After Last Infusion (wk) . |
|---|---|---|---|
| Gr. A No. 1 | 0.2 | SD | >19 (ongoing) |
| Gr. A No. 2 | 6.5 | SD | 3 |
| Gr. A No. 3 | 7.7 | SD | 8 |
| Gr. A No. 4 | 11.5 | PD | 0 |
| Gr. A No. 5 | 37.2 | SD | 3 |
| Gr. B No. 6 | 60.8 | SD | 8 |
| Gr. B No. 7 | 68.1 | CR | >36 (ongoing) |
| Gr. B No. 8 | 71.1 | PR | 19 |
| Gr. B No. 9 | 89.3 | SD | 3½ |
| Gr. B No. 10 | 124.0 | SD | 9 |
| Gr. B No. 11 | 294.3 | NE | NE |
| Patient . | Lymphocyte Counts (×109/L) at Baseline . | Response . | Time to Progression After Last Infusion (wk) . |
|---|---|---|---|
| Gr. A No. 1 | 0.2 | SD | >19 (ongoing) |
| Gr. A No. 2 | 6.5 | SD | 3 |
| Gr. A No. 3 | 7.7 | SD | 8 |
| Gr. A No. 4 | 11.5 | PD | 0 |
| Gr. A No. 5 | 37.2 | SD | 3 |
| Gr. B No. 6 | 60.8 | SD | 8 |
| Gr. B No. 7 | 68.1 | CR | >36 (ongoing) |
| Gr. B No. 8 | 71.1 | PR | 19 |
| Gr. B No. 9 | 89.3 | SD | 3½ |
| Gr. B No. 10 | 124.0 | SD | 9 |
| Gr. B No. 11 | 294.3 | NE | NE |
Abbreviations: NE, not evaluable for response because only 1 dose rituximab (375 mg/m2) was administered. SD, stable disease; PD, progressive disease; CR, complete remission; PR, partial remission.